Optimizing Biotech Investment Strategy in an Uncertain Market Landscape
Introduction: AUS-based mid-size biotech firm was preparing for its upcoming investment cycle to broaden its therapeutic area focus. The team had strong scientific instincts but lacked a unified, evidence-based approach to compare opportunities across disease areas, evaluate commercial risk, and pressure-test assumptions in volatile market conditions. Their existing datasets were scattered, inconsistent, and not structured to support quick, high-stakes investment calls. Objective: To build a sharper, data-anchored investment strategy that could: Identify high-potential assets with a clearer view of risk, timelines, and their alignment with the payer expectations Bring consistency to how the firm compares market opportunities across therapy areas Anticipate shifts in disease burden, spending, competition, pricing, and access that could influence long-term value Approach: We worked closely with the partners to redesign how they sourced, validat...